Developer docs
API playgroundTry for free, no card

Search company profiles

IAG, Image Analysis Group

Full company profile

uuid000714x

Namestring
IAG, Image Analysis Group
Legal namestring
Image Analysis Ltd Limited Company
Websiteurl
ia-grp.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Image Analysis Group (IAG) is a London-headquartered imaging contract research organization (iCRO) founded in 2007 that provides centralized image management, radiological review, and AI-enabled quantitative imaging analysis for clinical trials sponsored by pharmaceutical and biotechnology companies. The company has supported more than 700 trials globally across all phases and therapeutic areas including oncology, neuro-oncology, musculoskeletal and autoimmune diseases, metabolic and obesity indications, and rare diseases. Operating geographies span the UK, continental Europe, North America, India, China, Australia, and Africa, with functional offices in London and Schaumburg (US) and partnership-led operational support across Asia-Pacific.

IAG's core technology is DYNAMIKA™, a proprietary cloud-native clinical trial imaging platform that orchestrates the full imaging pipeline — image acquisition guidance, site uploads, de-identification, real-time quality control, central reads, quantitative analysis, and regulatory-ready data exports — across modalities including MRI, CT, PET, ultrasound, X-ray, and DXA. On top of the platform sit proprietary methodologies such as DEMRIQ (DCE-MRI quantification for synovial inflammation), integrated AI tooling from partners Better Medicine and Picture Health for oncology, and indication-specific scoring systems validated for FDA, EMA, and other regulatory submissions. Platform and processes are aligned to FDA 21 CFR Part 11, ISO 13485, GDPR, HIPAA, and SOC 2 Type II (completed March 2026).

IAG generates revenue through professional-services contracts for imaging CRO engagements — typically multi-year, quote-based, and structured around trial complexity, modality mix, site count, and service scope (startup, site training, central reads, adjudication, exploratory biomarkers, and DYNAMIKA licensing). Customers are predominantly enterprise pharma and biotech (Eli Lilly, Roche, Novo Nordisk, Amgen, Takeda, Ferring) plus academic research consortia, sold via direct enterprise field sales rather than resellers, with thought-leadership content and presence at conferences such as SCOPE Summit, IO360, and HBI driving top-of-funnel demand.

Short descriptiontext

IAG is a London-based imaging CRO whose DYNAMIKA™ platform centralizes image management, central reads, and AI-enabled quantitative analysis for clinical trials. It serves pharmaceutical and biotechnology sponsors across oncology, immunology, neurology, metabolic, and rare disease programs globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial imaging, imaging contract research, medical image analysis, oncology imaging services, quantitative imaging biomarkers
Industry1 code
PRIMARYHLAGACAL
Site Data Management Support (EDC/Source/SDV Readiness)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Custom Computer Programming Services541511
  • Software Publishers5132
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Prepackaged Software7372
Product category
Imaging Contract Research Services (Clinical Trial Imaging)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Imaging CRO Services
TypeProfessional Services
Description

IAG provides end-to-end imaging contract research services for clinical trials across all phases (Phase I-III) and therapeutic areas. Revenue is generated through service contracts that include imaging charter development, site training, data management, central reads, adjudication, and platform licensing. Pricing is structured around trial complexity, number of sites, imaging modalities, and service scope including optional AI-enabled biomarkers and country expansions.

ia-grp.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Trial-specific pricing based on scope and complexity
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is structured around clear workstreams including: trial complexity and phase, number of sites and patients, imaging modalities and endpoints, service scope from site setup through regulatory support. Optional add-ons for AI-enabled biomarkers and additional reads.

ia-grp.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DYNAMIKA™
Description

Proprietary cloud-based clinical trial imaging platform that centralizes image management, quality control, central review, and AI-enabled analytics for clinical trials.

ia-grp.com
Core offering1 text field

IAG is a science-driven imaging contract research organization (iCRO) that provides end-to-end centralized imaging services for pharmaceutical and biotech clinical trials across all phases and therapeutic areas. Its proprietary DYNAMIKA™ cloud-native platform orchestrates image acquisition, quality control, central reads, AI-enabled quantitative analysis, and regulatory-ready data exports, complemented by therapeutic-area imaging services in oncology, neuro-oncology, musculoskeletal, liver/metabolic, and rare diseases. Revenue is generated through service contracts (imaging charter development, site training, data management, central reads, adjudication) bundled with platform licensing for sponsors conducting global clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Protocol deviations related to imaging dropped by 40% in pivotal phase III oncology trial with 80+ global sites
+4 more records
Product overview1 text field

IAG is a science-driven imaging CRO that operates primarily through its cloud-native DYNAMIKA™ platform, which serves as the central operating system for all clinical trial imaging activities. The platform unifies image acquisition guidance, site uploads, de-identification, quality control, central reads, quantitative analysis, and regulatory-ready data exports. IAG complements the platform with therapeutic area-specific imaging services spanning early and late phase clinical trials, real-world evidence studies, and specialized offerings in oncology, neuro-oncology, musculoskeletal diseases, liver/metabolic diseases, and rare disorders. The DEMRIQ (DCE-MRI Quantification) methodology provides proprietary AI-driven quantitative imaging biomarkers for inflammation assessment. The Collect and Hold solution offers budget-friendly data storage without immediate central review, while AI integrations with Better Medicine and Picture Health extend the platform's automated tumor assessment and imaging biomarker capabilities.

Product and service10 records
1DYNAMIKA™ Clinical Trial Imaging Platform
CategoryClinical Trial Imaging Platform / Software
Description

Cloud-native platform that centralizes image acquisition, quality control, anonymization, transfer, central review, and regulatory-ready data exports for clinical trials, with AI-enabled workflows, real-time dashboards, configurable reading forms, and integrated eCRFs for imaging endpoints across all phases and therapeutic areas. Sold to pharmaceutical and biotech sponsors.

2Early Phase Clinical Trial Imaging
CategoryClinical Trial Imaging Services
Description

Imaging support service for Phase I and early Phase II trials focusing on safety, pharmacokinetics, and initial efficacy evidence, including optimal imaging strategy selection, mechanism-of-action assessment, and quantitative endpoint design for oncology, immunology, and rare diseases. Targeted at pharmaceutical and biotech sponsors.

3Late Phase Clinical Trial Imaging
CategoryClinical Trial Imaging Services
Description

Comprehensive imaging support service for Phase III pivotal and global multicenter trials, including real-time QC, digital site training, integrated reader management, sophisticated analytics, and audit-ready data for regulatory submissions. Targeted at pharmaceutical and biotech sponsors running pivotal trials.

4Collect and Hold Imaging Solution
CategoryClinical Trial Imaging Services
Description

Budget-friendly imaging data management service where imaging data is prospectively collected, quality-controlled, and securely stored without immediate central review, with retrospective analysis as required. Targeted at sponsors seeking lower-cost imaging data capture.

5Real-World Evidence and AI Imaging Studies
CategoryAI Imaging Analytics Services
Description

Real-world evidence studies and AI-driven imaging analysis services that complement traditional clinical and claims data with objective visual imaging endpoints. Targeted at pharmaceutical and biotech sponsors seeking AI-enabled biomarker validation.

6Bone Health and Osteoporosis Imaging
CategoryTherapeutic Area Imaging Service
Description

End-to-end imaging support service for bone health and osteoporosis clinical trials using DXA, QCT, X-ray, and MRI to measure bone mineral density, microarchitecture, and fracture risk with regulatory-grade endpoints. Targeted at sponsors developing osteoporosis and bone fragility therapies.

7Oncology Imaging
CategoryTherapeutic Area Imaging Service
Description

Comprehensive imaging support service for solid tumor, hematologic malignancy, and sarcoma trials using MRI, CT, PET, and ultrasound with standardized criteria (RECIST, iRECIST, volumetric analysis) and AI-enhanced tumor assessment. Targeted at oncology drug developers.

8Neuro-Oncology Imaging
CategoryTherapeutic Area Imaging Service
Description

Specialist imaging CRO service for GBM and glioma studies using standardized RANO and RANO 2.0 reads, molecular imaging, and advanced MRI (DWI, DCE-MRI) to distinguish true progression from pseudo-progression. Targeted at sponsors developing brain tumor therapies.

9Musculoskeletal Imaging
CategoryTherapeutic Area Imaging Service
Description

Imaging service for osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and myositis using X-ray, MRI, DCE-MRI, CT, ultrasound, and DXA with indication-specific scoring systems. Targeted at sponsors developing therapies in inflammatory and autoimmune diseases.

10Liver Disease and MASH/NASH Imaging
CategoryTherapeutic Area Imaging Service
Description

Standardized MRI protocol service including MRI-PDFF for liver fat quantification and MR elastography for non-invasive fibrosis assessment, supporting patient selection and efficacy endpoints in metabolic liver disease studies. Targeted at sponsors developing MASH/NASH and metabolic liver disease therapies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Strategic partnership to deliver fully integrated cardiac safety monitoring and imaging core lab services to pharmaceutical and biotechnology sponsors worldwide. Combines HeartcoR's core lab services (ECG, cardiac monitoring, endpoint adjudication) with IAG's multimodality imaging expertise and DYNAMIKA platform. Creates an end-to-end workflow under unified governance to address fragmented vendor relationships and provide coordinated cardiac and imaging data for regulatory submissions.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-11
Description

Strategic partnership to enhance oncology clinical trial imaging through AI integration. Better Medicine's AI tools are embedded into IAG's DYNAMIKA platform to automate tumor assessment processes, reducing turnaround times and costs while maintaining regulatory standards.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-09
Description

AI-powered oncology imaging partnership for faster, more precise clinical trials. Integrates Picture Health's AI capabilities with DYNAMIKA platform for tumor response data and imaging biomarker analysis.

4WHO-ESCEO-IOF PRECCO
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Partnership on osteoporosis and bone health research using advanced imaging. Supports global bone health initiatives and clinical trials for osteoporosis treatments.

ia-grp.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

AI-driven imaging collaboration for fertility and women's health using real-world ultrasound data from Fertility Centers of Illinois and Dexeus in Barcelona. The partnership aims to validate predictive AI models for identifying optimal conception timing and create regulator-ready imaging endpoints for fertility clinical trials. This collaboration represents one of the first efforts to translate AI-driven imaging biomarkers from clinical trials into real-world fertility practice.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-08
Description

Long-standing strategic collaboration on AI-powered MRI for IBD clinical trials, with IAG leading imaging strategy and AI-enabled image analysis using DYNAMIKA platform. Partnership has expanded to include obesity and metabolic disease imaging programs.

7Robarts Clinical Trials
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-08
Description

Strategic collaboration with IAG and Eli Lilly to validate AI-enabled MRI biomarkers for Crohn's disease. Robarts provides clinical expertise and patient-focused insights for endpoint validation in IBD trials.

ia-grp.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Perspectum develops AI-driven quantitative imaging biomarkers, particularly in metabolic and liver disease, and partners with pharma on clinical trials. Comparable to IAG's liver/MASH imaging and AI biomarker work.

TypeEmerging player
Description

Median Technologies offers iCRO imaging services and AI-based image analysis for oncology clinical trials. Direct overlap with IAG's oncology imaging and AI-enabled tumor assessment offerings.

TypeEmerging player
Description

QMENTA provides a cloud imaging platform for clinical trials and research, focused on neurology. It competes with IAG's DYNAMIKA in CNS trial image management and AI biomarker delivery.

TypeBroad incumbent
Description

Labcorp's drug development segment (formerly Covance) operates a large central laboratory and imaging services business. Overlaps with IAG in clinical trial imaging endpoints and central review for pharma sponsors.

5IXICO
TypeDirect peer
Description

IXICO is a specialist imaging CRO focused on neuroscience and rare disease clinical trials using AI-enabled image analysis. Comparable to IAG's neuro-oncology and quantitative imaging biomarker work, especially in CNS trials.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with imaging capabilities embedded in its full-service portfolio. Competes for the same large pharma trials as IAG but bundles imaging with broader clinical and commercial services.

TypeDirect peer
Description

Clario (formed from the merger of BioClinica and ERT) is a dedicated imaging and eCOA CRO serving global clinical trials. It is the most direct competitor to IAG's imaging CRO and DYNAMIKA-style platform offerings across oncology, neurology, and musculoskeletal indications.

TypeBroad incumbent
Description

ICON is a top-3 global CRO with established imaging and biomarker services. It is a broad incumbent competitor to IAG, especially on pivotal Phase III programs where sponsors prefer single-vendor outsourcing.

TypeDirect peer
Description

Calyx (formerly Parexel Informatics) offers medical imaging management and eClinical solutions for clinical trials. Competes with IAG in central imaging review, regulatory submission support, and platform-based trial enablement.

TypeDirect peer
Description

Invicro, now part of Medpace, provides imaging core lab and biomarker services for clinical trials across oncology and CNS. Directly comparable to IAG's full-service imaging CRO model and platform-driven central reads.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IAG, Image Analysis Group

Imaging Contract Research Services (Clinical Trial Imaging)ia-grp.com

IAG is a London-based imaging CRO whose DYNAMIKA™ platform centralizes image management, central reads, and AI-enabled quantitative analysis for clinical trials. It serves pharmaceutical and biotechnology sponsors across oncology, immunology, neurology, metabolic, and rare disease programs globally.

What IAG, Image Analysis Group does

Image Analysis Group (IAG) is a London-headquartered imaging contract research organization (iCRO) founded in 2007 that provides centralized image management, radiological review, and AI-enabled quantitative imaging analysis for clinical trials sponsored by pharmaceutical and biotechnology companies. The company has supported more than 700 trials globally across all phases and therapeutic areas including oncology, neuro-oncology, musculoskeletal and autoimmune diseases, metabolic and obesity indications, and rare diseases. Operating geographies span the UK, continental Europe, North America, India, China, Australia, and Africa, with functional offices in London and Schaumburg (US) and partnership-led operational support across Asia-Pacific.

IAG's core technology is DYNAMIKA™, a proprietary cloud-native clinical trial imaging platform that orchestrates the full imaging pipeline — image acquisition guidance, site uploads, de-identification, real-time quality control, central reads, quantitative analysis, and regulatory-ready data exports — across modalities including MRI, CT, PET, ultrasound, X-ray, and DXA. On top of the platform sit proprietary methodologies such as DEMRIQ (DCE-MRI quantification for synovial inflammation), integrated AI tooling from partners Better Medicine and Picture Health for oncology, and indication-specific scoring systems validated for FDA, EMA, and other regulatory submissions. Platform and processes are aligned to FDA 21 CFR Part 11, ISO 13485, GDPR, HIPAA, and SOC 2 Type II (completed March 2026).

IAG generates revenue through professional-services contracts for imaging CRO engagements — typically multi-year, quote-based, and structured around trial complexity, modality mix, site count, and service scope (startup, site training, central reads, adjudication, exploratory biomarkers, and DYNAMIKA licensing). Customers are predominantly enterprise pharma and biotech (Eli Lilly, Roche, Novo Nordisk, Amgen, Takeda, Ferring) plus academic research consortia, sold via direct enterprise field sales rather than resellers, with thought-leadership content and presence at conferences such as SCOPE Summit, IO360, and HBI driving top-of-funnel demand.

IAG, Image Analysis Group firmographics

Firmographics
Name
IAG, Image Analysis Group
Legal name
Image Analysis Ltd Limited Company
Website
https://ia-grp.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
IAG is a London-based imaging CRO whose DYNAMIKA™ platform centralizes image management, central reads, and AI-enabled quantitative analysis for clinical trials. It serves pharmaceutical and biotechnology sponsors across oncology, immunology, neurology, metabolic, and rare disease programs globally.
Ownership category
akta.pro rank

IAG, Image Analysis Group industry classification

Industry
Product category
Imaging Contract Research Services (Clinical Trial Imaging)
NAICS
Scientific Research and Development Services (5417), Custom Computer Programming Services (541511), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGACAL
Site Data Management Support (EDC/Source/SDV Readiness)

Keywords

  • Clinical trial imaging
  • Imaging contract research
  • Medical image analysis
  • Oncology imaging services
  • Quantitative imaging biomarkers

Where IAG, Image Analysis Group is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices6 records

Markets served

IAG, Image Analysis Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Imaging CRO Services: IAG provides end-to-end imaging contract research services for clinical trials across all phases (Phase I-III) and therapeutic areas. Revenue is generated through service contracts that include imaging charter development, site training, data management, central reads, adjudication, and platform licensing. Pricing is structured around trial complexity, number of sites, imaging modalities, and service scope including optional AI-enabled biomarkers and country expansions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTrial-specific pricing based on scope and complexity

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

IAG, Image Analysis Group product offering

Product offering

Core offering

IAG is a science-driven imaging contract research organization (iCRO) that provides end-to-end centralized imaging services for pharmaceutical and biotech clinical trials across all phases and therapeutic areas. Its proprietary DYNAMIKA™ cloud-native platform orchestrates image acquisition, quality control, central reads, AI-enabled quantitative analysis, and regulatory-ready data exports, complemented by therapeutic-area imaging services in oncology, neuro-oncology, musculoskeletal, liver/metabolic, and rare diseases. Revenue is generated through service contracts (imaging charter development, site training, data management, central reads, adjudication) bundled with platform licensing for sponsors conducting global clinical trials.

Product overview

IAG is a science-driven imaging CRO that operates primarily through its cloud-native DYNAMIKA™ platform, which serves as the central operating system for all clinical trial imaging activities. The platform unifies image acquisition guidance, site uploads, de-identification, quality control, central reads, quantitative analysis, and regulatory-ready data exports. IAG complements the platform with therapeutic area-specific imaging services spanning early and late phase clinical trials, real-world evidence studies, and specialized offerings in oncology, neuro-oncology, musculoskeletal diseases, liver/metabolic diseases, and rare disorders. The DEMRIQ (DCE-MRI Quantification) methodology provides proprietary AI-driven quantitative imaging biomarkers for inflammation assessment. The Collect and Hold solution offers budget-friendly data storage without immediate central review, while AI integrations with Better Medicine and Picture Health extend the platform's automated tumor assessment and imaging biomarker capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • DYNAMIKA™: Proprietary cloud-based clinical trial imaging platform that centralizes image management, quality control, central review, and AI-enabled analytics for clinical trials.

Products and services

  • DYNAMIKA™ Clinical Trial Imaging Platform Cloud-native platform that centralizes image acquisition, quality control, anonymization, transfer, central review, and regulatory-ready data exports for clinical trials, with AI-enabled workflows, real-time dashboards, configurable reading forms, and integrated eCRFs for imaging endpoints across all phases and therapeutic areas. Sold to pharmaceutical and biotech sponsors.
  • Early Phase Clinical Trial Imaging Imaging support service for Phase I and early Phase II trials focusing on safety, pharmacokinetics, and initial efficacy evidence, including optimal imaging strategy selection, mechanism-of-action assessment, and quantitative endpoint design for oncology, immunology, and rare diseases. Targeted at pharmaceutical and biotech sponsors.
  • Late Phase Clinical Trial Imaging Comprehensive imaging support service for Phase III pivotal and global multicenter trials, including real-time QC, digital site training, integrated reader management, sophisticated analytics, and audit-ready data for regulatory submissions. Targeted at pharmaceutical and biotech sponsors running pivotal trials.
  • Collect and Hold Imaging Solution Budget-friendly imaging data management service where imaging data is prospectively collected, quality-controlled, and securely stored without immediate central review, with retrospective analysis as required. Targeted at sponsors seeking lower-cost imaging data capture.
  • Real-World Evidence and AI Imaging Studies Real-world evidence studies and AI-driven imaging analysis services that complement traditional clinical and claims data with objective visual imaging endpoints. Targeted at pharmaceutical and biotech sponsors seeking AI-enabled biomarker validation.
  • Bone Health and Osteoporosis Imaging End-to-end imaging support service for bone health and osteoporosis clinical trials using DXA, QCT, X-ray, and MRI to measure bone mineral density, microarchitecture, and fracture risk with regulatory-grade endpoints. Targeted at sponsors developing osteoporosis and bone fragility therapies.
  • Oncology Imaging Comprehensive imaging support service for solid tumor, hematologic malignancy, and sarcoma trials using MRI, CT, PET, and ultrasound with standardized criteria (RECIST, iRECIST, volumetric analysis) and AI-enhanced tumor assessment. Targeted at oncology drug developers.
  • Neuro-Oncology Imaging Specialist imaging CRO service for GBM and glioma studies using standardized RANO and RANO 2.0 reads, molecular imaging, and advanced MRI (DWI, DCE-MRI) to distinguish true progression from pseudo-progression. Targeted at sponsors developing brain tumor therapies.
  • Musculoskeletal Imaging Imaging service for osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and myositis using X-ray, MRI, DCE-MRI, CT, ultrasound, and DXA with indication-specific scoring systems. Targeted at sponsors developing therapies in inflammatory and autoimmune diseases.
  • Liver Disease and MASH/NASH Imaging Standardized MRI protocol service including MRI-PDFF for liver fat quantification and MR elastography for non-invasive fibrosis assessment, supporting patient selection and efficacy endpoints in metabolic liver disease studies. Targeted at sponsors developing MASH/NASH and metabolic liver disease therapies.

Quantifiable outcome

  • Protocol deviations related to imaging dropped by 40% in pivotal phase III oncology trial with 80+ global sites
  • +4 more outcomes

Companies that use IAG, Image Analysis Group

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

IAG, Image Analysis Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

IAG, Image Analysis Group partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • HeartcoR SolutionscoreStrategic or Co-development Partner · 6 May 2026Strategic partnership to deliver fully integrated cardiac safety monitoring and imaging core lab services to pharmaceutical and biotechnology sponsors worldwide. Combines HeartcoR's core lab services (ECG, cardiac monitoring, endpoint adjudication) with IAG's multimodality imaging expertise and DYNAMIKA platform. Creates an end-to-end workflow under unified governance to address fragmented vendor relationships and provide coordinated cardiac and imaging data for regulatory submissions.
  • Better MedicinecoreTechnology or Integration · 11 December 2025Strategic partnership to enhance oncology clinical trial imaging through AI integration. Better Medicine's AI tools are embedded into IAG's DYNAMIKA platform to automate tumor assessment processes, reducing turnaround times and costs while maintaining regulatory standards.
  • Picture HealthcoreTechnology or Integration · 9 December 2025AI-powered oncology imaging partnership for faster, more precise clinical trials. Integrates Picture Health's AI capabilities with DYNAMIKA platform for tumor response data and imaging biomarker analysis.
  • WHO-ESCEO-IOF PRECCOmajorStrategic or Co-development Partner · 3 December 2025Partnership on osteoporosis and bone health research using advanced imaging. Supports global bone health initiatives and clinical trials for osteoporosis treatments.
  • Ferring PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024AI-driven imaging collaboration for fertility and women's health using real-world ultrasound data from Fertility Centers of Illinois and Dexeus in Barcelona. The partnership aims to validate predictive AI models for identifying optimal conception timing and create regulator-ready imaging endpoints for fertility clinical trials. This collaboration represents one of the first efforts to translate AI-driven imaging biomarkers from clinical trials into real-world fertility practice.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 8 May 2019Long-standing strategic collaboration on AI-powered MRI for IBD clinical trials, with IAG leading imaging strategy and AI-enabled image analysis using DYNAMIKA platform. Partnership has expanded to include obesity and metabolic disease imaging programs.
  • Robarts Clinical TrialscoreStrategic or Co-development Partner · 8 May 2019Strategic collaboration with IAG and Eli Lilly to validate AI-enabled MRI biomarkers for Crohn's disease. Robarts provides clinical expertise and patient-focused insights for endpoint validation in IBD trials.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

IAG, Image Analysis Group competitors and assessment

Company assessment

Emerging players

  • Perspectum: Perspectum develops AI-driven quantitative imaging biomarkers, particularly in metabolic and liver disease, and partners with pharma on clinical trials. Comparable to IAG's liver/MASH imaging and AI biomarker work.
  • Median Technologies: Median Technologies offers iCRO imaging services and AI-based image analysis for oncology clinical trials. Direct overlap with IAG's oncology imaging and AI-enabled tumor assessment offerings.
  • QMENTA: QMENTA provides a cloud imaging platform for clinical trials and research, focused on neurology. It competes with IAG's DYNAMIKA in CNS trial image management and AI biomarker delivery.

Broad incumbents

  • Labcorp Drug Development: Labcorp's drug development segment (formerly Covance) operates a large central laboratory and imaging services business. Overlaps with IAG in clinical trial imaging endpoints and central review for pharma sponsors.
  • IQVIA: IQVIA is the world's largest CRO with imaging capabilities embedded in its full-service portfolio. Competes for the same large pharma trials as IAG but bundles imaging with broader clinical and commercial services.
  • ICON plc: ICON is a top-3 global CRO with established imaging and biomarker services. It is a broad incumbent competitor to IAG, especially on pivotal Phase III programs where sponsors prefer single-vendor outsourcing.

Direct peers

  • IXICO: IXICO is a specialist imaging CRO focused on neuroscience and rare disease clinical trials using AI-enabled image analysis. Comparable to IAG's neuro-oncology and quantitative imaging biomarker work, especially in CNS trials.
  • Clario: Clario (formed from the merger of BioClinica and ERT) is a dedicated imaging and eCOA CRO serving global clinical trials. It is the most direct competitor to IAG's imaging CRO and DYNAMIKA-style platform offerings across oncology, neurology, and musculoskeletal indications.
  • Calyx: Calyx (formerly Parexel Informatics) offers medical imaging management and eClinical solutions for clinical trials. Competes with IAG in central imaging review, regulatory submission support, and platform-based trial enablement.
  • Invicro (Medpace): Invicro, now part of Medpace, provides imaging core lab and biomarker services for clinical trials across oncology and CNS. Directly comparable to IAG's full-service imaging CRO model and platform-driven central reads.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

IAG, Image Analysis Group social profiles

Digital presence

IAG, Image Analysis Group compliance and trust

Trust signal

Compliance5 records

IAG, Image Analysis Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IAG, Image Analysis Group leadership team

Management profile

Number of profiles

Profiles6 records

IAG, Image Analysis Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IAG, Image Analysis Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IAG, Image Analysis Group

What does IAG, Image Analysis Group do?

IAG is a science-driven imaging contract research organization (iCRO) that provides end-to-end centralized imaging services for pharmaceutical and biotech clinical trials across all phases and therapeutic areas. Its proprietary DYNAMIKA™ cloud-native platform orchestrates image acquisition, quality control, central reads, AI-enabled quantitative analysis, and regulatory-ready data exports, complemented by therapeutic-area imaging services in oncology, neuro-oncology, musculoskeletal, liver/metabolic, and rare diseases. Revenue is generated through service contracts (imaging charter development, site training, data management, central reads, adjudication) bundled with platform licensing for sponsors conducting global clinical trials.

Is IAG, Image Analysis Group a public or private company?

IAG, Image Analysis Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IAG, Image Analysis Group founded?

IAG, Image Analysis Group was founded in 2007. It employs 51 to 100 people.

Where is IAG, Image Analysis Group based?

IAG, Image Analysis Group is headquartered in London, United Kingdom, in the Europe region.

How does IAG, Image Analysis Group make money?

One revenue line is on record: imaging CRO Services.

Who are IAG, Image Analysis Group's main competitors?

Emerging players on record are Perspectum, Median Technologies and QMENTA. Broad incumbents are Labcorp Drug Development, IQVIA and ICON plc. Direct peers are IXICO, Clario, Calyx and Invicro (Medpace).

Does IAG, Image Analysis Group have an API?

No public API is recorded for IAG, Image Analysis Group.

What industry is IAG, Image Analysis Group in?

IAG, Image Analysis Group's product category is Imaging Contract Research Services (Clinical Trial Imaging). Its primary akta.pro industry code is HLAGACAL, Site Data Management Support (EDC/Source/SDV Readiness). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireImage Analysis Group (IAG) Joins €13 Million EU-Funded ExoCordOA Consortium as Imaging PartnerImage Analysis Group joined the €13 million ExoCordOA consortium as imaging partner, supporting patient stratification and structural evidence for EXO-101, a secretome-based osteoarthritis therapy. The five-year Horizon Europe project, led by Exogenus Therapeutics, aims to advance EXO-101 toward clinical validation as a disease-modifying treatment.EIN PresswireImage Analysis Group (IAG) Joins €13 Million EU-Funded ExoCordOA Consortium as Imaging PartnerImage Analysis Group joined the €13 million ExoCordOA consortium as imaging partner, supporting patient stratification and structural evidence for EXO-101, a secretome-based osteoarthritis therapy. The five-year Horizon Europe project, led by Exogenus Therapeutics, aims to advance EXO-101 toward clinical validation as a disease-modifying treatment.EIN PresswireImage Analysis Group (IAG) and Resonance Health Announce Global Strategic Partnership in Clinical Trial ImagingImage Analysis Group and Resonance Health announced a global strategic partnership combining IAG's DYNAMIKA platform and Resonance's regulatory-cleared quantitative MRI endpoints. The collaboration targets obesity and metabolic trials, with initial engagements planned across Europe, the US, Australia, and China. Resonance's revenue grew from $4 million in FY23 to $16 million in FY26.EIN PresswireImage Analysis Group (IAG) Expands U.S. Presence with New Boston-Area Office OpeningImage Analysis Group (IAG) opened a new U.S. office in Cambridge, Massachusetts, to support imaging-driven clinical trials. The expansion plans local hires over 12–24 months and aims to strengthen partnerships with biotech and pharma sponsors. The company, founded in 2007, operates globally with hubs in the UK, US, EU, and India.YahooImage Analysis Group (IAG) and HeartcoR Solutions Announce Strategic Partnership to Deliver Integrated Cardiac Safety and Imaging Core Lab Services for Clinical TrialsImage Analysis Group (IAG) and HeartcoR Solutions announced a strategic partnership on May 6, 2026, to deliver fully integrated cardiac safety monitoring and imaging services to pharmaceutical and biotechnology sponsors worldwide. The partnership combines HeartcoR's core lab services (ECG, cardiac monitoring, endpoint adjudication) with IAG's multimodality imaging expertise and DYNAMIKA™ cloud platform to create an end-to-end workflow under unified governance. The collaboration aims to address fragmented data flows and operational burden by offering sponsors a single point of accountability and seamless data integration across cardiac and imaging modalities for regulatory submissions.DAICImage Analysis Group, HeartcoR Solutions Partner to Deliver Integrated Cardiac Safety, Imaging Core Lab Services for Clinical TrialsImage Analysis Group (IAG), a global imaging contract research organization headquartered in London, and HeartcoR Solutions announced a strategic partnership to deliver integrated cardiac safety monitoring and imaging core lab services to pharmaceutical and biotechnology sponsors. The partnership combines HeartcoR's core lab services (ECG, Cardiac Monitoring, Endpoint Adjudication) with IAG's multimodality imaging expertise and DYNAMIKA technology platform, creating an end-to-end workflow within a unified operational and data environment. The collaboration aims to reduce fragmented vendor relationships and operational burden while providing coordinated ECG, cardiac safety, and imaging data to support regulatory submissions to global health authorities.PR NewswireImage Analysis Group (IAG) and HeartcoR Solutions Announce Strategic Partnership to Deliver Integrated Cardiac Safety and Imaging Core Lab Services for Clinical TrialsImage Analysis Group (IAG), a London-headquartered global imaging CRO, and HeartcoR Solutions, a Schaumburg, IL-based specialized cardiac safety core lab, announced a strategic partnership to deliver fully integrated cardiac safety monitoring and imaging services to pharmaceutical and biotechnology sponsors worldwide. The partnership combines HeartcoR's ECG, cardiac monitoring, and endpoint adjudication services with IAG's multimodality imaging core lab expertise and DYNAMIKA™ technology platform, creating an end-to-end workflow within a unified operational and data environment. This integration addresses a common industry challenge of fragmented vendor relationships by enabling sponsors to reduce the number of vendors, access data faster, and strengthen safety and efficacy narratives for regulatory submissions.EIN PresswireImage Analysis Group × HeartcoR Solutions – Press ReleaseImage Analysis Group and HeartcoR Solutions announced a strategic partnership to deliver integrated cardiac safety monitoring and imaging services to pharmaceutical and biotechnology sponsors. The collaboration combines HeartcoR's cardiac safety core lab services with IAG's imaging core lab and DYNAMIKA platform, aiming to streamline operations and support regulatory submissions.EIN PresswireImage Analysis Group Achieves SOC 2 Type II Certification, Setting the Enterprise Benchmark for Global Imaging CROsImage Analysis Group (IAG) announced it achieved SOC 2 Type II certification, validating the security, confidentiality, and operational controls of its DYNAMIKA™ imaging platform over a 12-month period. The certification underscores IAG's compliance with stringent data security standards for global clinical trials involving sensitive imaging data.EIN PresswireImage Analysis Group Expands Executive Leadership Across Quality and FinanceImage Analysis Group (IAG), a clinical trial imaging and data solutions company, announced two strategic executive appointments: Derek Hunter as Head of Quality and Jonathan Shaul as Chief Financial Officer. Hunter brings over 20 years of quality management experience in life sciences and will oversee IAG's quality systems and imaging data integrity, while Shaul will lead financial strategy and operational efficiency for the company's global operations. The company stated these appointments come at a pivotal time as it continues partnering with biotech, pharmaceutical, and clinical research organizations on complex clinical trials worldwide.